Walvax Biotechnology Co Ltd
SZSE:300142
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
9.9
24.78
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Walvax Biotechnology Co Ltd
Unrealized Security Profit/Loss
Walvax Biotechnology Co Ltd
Unrealized Security Profit/Loss Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Unrealized Security Profit/Loss | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
W
|
Walvax Biotechnology Co Ltd
SZSE:300142
|
Unrealized Security Profit/Loss
ÂĄ217.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Unrealized Security Profit/Loss
ÂĄ9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Unrealized Security Profit/Loss
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Unrealized Security Profit/Loss
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Unrealized Security Profit/Loss
ÂĄ328.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Unrealized Security Profit/Loss
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Walvax Biotechnology Co Ltd
Glance View
Walvax Biotechnology Co., Ltd. engages in the research and development, production, and sale of biopharmaceutical products. The company is headquartered in Kunming, Yunnan and currently employs 1,866 full-time employees. The company went IPO on 2010-11-12. The Company’s main products include haemophilus influenza type b conjugate vaccines, freeze-dried group A,C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines and group A and C meningococcal polysaccharide vaccines, among others. The firm distributes its products mainly in domestic market.
See Also
What is Walvax Biotechnology Co Ltd's Unrealized Security Profit/Loss?
Unrealized Security Profit/Loss
217.2m
CNY
Based on the financial report for Jun 30, 2024, Walvax Biotechnology Co Ltd's Unrealized Security Profit/Loss amounts to 217.2m CNY.
What is Walvax Biotechnology Co Ltd's Unrealized Security Profit/Loss growth rate?
Unrealized Security Profit/Loss CAGR 1Y
0%
Over the last year, the Unrealized Security Profit/Loss growth was 0%.